Next Article in Journal
Long-Term Exposure to Oroxylin A Inhibits Metastasis by Suppressing CCL2 in Oral Squamous Cell Carcinoma Cells
Next Article in Special Issue
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Previous Article in Journal
Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood
Previous Article in Special Issue
Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift

BRCA2 and Other DDR Genes in Prostate Cancer

Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, 28029 Madrid, Spain
CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), 29010 Málaga, Spain
Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
Medical Oncology Department, Hospital Universitario Quironsalud Madrid, 28223 Madrid, Spain
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 352;
Received: 18 January 2019 / Revised: 11 February 2019 / Accepted: 4 March 2019 / Published: 12 March 2019
(This article belongs to the Special Issue BRCA Mutations and Cancer)
Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients. View Full-Text
Keywords: BRCA2; DNA damage and repair; DDR; prostate cancer; PARP inhibitors BRCA2; DNA damage and repair; DDR; prostate cancer; PARP inhibitors
MDPI and ACS Style

Nombela, P.; Lozano, R.; Aytes, A.; Mateo, J.; Olmos, D.; Castro, E. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers 2019, 11, 352.

AMA Style

Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers. 2019; 11(3):352.

Chicago/Turabian Style

Nombela, Paz, Rebeca Lozano, Alvaro Aytes, Joaquin Mateo, David Olmos, and Elena Castro. 2019. "BRCA2 and Other DDR Genes in Prostate Cancer" Cancers 11, no. 3: 352.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop